The estimated Net Worth of Mark Howard Snyder is at least $847 mil dollars as of 16 February 2024. Mr Snyder owns over 4,796 units of Halozyme Therapeutics stock worth over $846,723 and over the last 3 years he sold HALO stock worth over $0.
Mr has made over 3 trades of the Halozyme Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 4,796 units of HALO stock worth $284,834 on 16 February 2024.
The largest trade he's ever made was exercising 7,611 units of Halozyme Therapeutics stock on 3 January 2024 worth over $452,017. On average, Mr trades about 2,860 units every 58 days since 2022. As of 16 February 2024 he still owns at least 14,257 units of Halozyme Therapeutics stock.
You can see the complete history of Mr Snyder stock trades at the bottom of the page.
Mark Snyder is the Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. at Halozyme Therapeutics.
Mark's mailing address filed with the SEC is C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130.
Over the last 18 years, insiders at Halozyme Therapeutics have traded over $92,345,799 worth of Halozyme Therapeutics stock and bought 9,720,772 units worth $67,958,365 . The most active insiders traders include Randal J Kirk, David A Ramsay y Gregory Ian Frost. On average, Halozyme Therapeutics executives and independent directors trade stock every 21 days with the average trade being worth of $3,961,432. The most recent stock trade was executed by Michael J. La Barre on 27 August 2024, trading 5,580 units of HALO stock currently worth $102,728.
we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
Halozyme Therapeutics executives and other stock owners filed with the SEC include: